Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANK P HULL

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1407832744
CMS profile
335555
Location
PLANTATION, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$24,391.39

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANK P HULL

NPI 1407832744 · CMS profile ID 335555

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

PLANTATION, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407832744?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANK P HULL, NPI 1407832744, CMS profile ID 335555. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407832744?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). FRANK P HULL, NPI 1407832744, CMS profile ID 335555. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407832744?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
FRANK P HULL, NPI 1407832744, CMS profile ID 335555, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1407832744?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $24,391.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Intuitive Surgical, Inc. $3,000.0008/19/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960621349 CMS
Intuitive Surgical, Inc. $121.0008/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960651185 CMS
Mylan Specialty L.P. $23.9708/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963919811 CMS
Intuitive Surgical, Inc. $19.0008/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960651183 CMS
Intuitive Surgical, Inc. $587.9208/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960651191 CMS
Mallinckrodt Hospital Products Inc. $34.9208/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937502887 CMS
Mallinckrodt Hospital Products Inc. $9.9608/12/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937502889 CMS
Actelion Pharmaceuticals US, Inc. $76.9908/10/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885382409 CMS
AstraZeneca Pharmaceuticals LP $21.9807/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920249779 CMS
Actelion Pharmaceuticals US, Inc. $36.6307/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885382423 CMS
Regeneron Healthcare Solutions, Inc. $33.2807/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927209097 CMS
Insmed, Inc. $16.2706/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906449487 CMS
Pinnacle Biologics, Inc $300.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889234057 CMS
AstraZeneca Pharmaceuticals LP $18.0006/27/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920248087 CMS
Alexion Pharmaceuticals, Inc. $20.5406/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920249051 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.8306/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929850323 CMS
GlaxoSmithKline, LLC. $22.6206/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945137343 CMS
Actelion Pharmaceuticals US, Inc. $23.5406/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885382413 CMS
GlaxoSmithKline, LLC. $24.8505/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945137339 CMS
Amgen Inc. $22.0105/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939220705 CMS
Actelion Pharmaceuticals US, Inc. $35.3205/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885382419 CMS
Actelion Pharmaceuticals US, Inc. $29.1305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885382421 CMS
AstraZeneca Pharmaceuticals LP $18.4105/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920231357 CMS
AstraZeneca Pharmaceuticals LP $19.3805/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920262387 CMS
Regeneron Healthcare Solutions, Inc. $7.5305/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927209087 CMS
Regeneron Healthcare Solutions, Inc. $3.8405/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927209091 CMS
Actelion Pharmaceuticals US, Inc. $36.5105/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885382415 CMS
Mallinckrodt Hospital Products Inc. $34.2105/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937502885 CMS
AstraZeneca Pharmaceuticals LP $21.6404/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920243423 CMS
Merck Sharp & Dohme LLC $18.0304/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944347021 CMS
Actelion Pharmaceuticals US, Inc. $19.3004/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885382411 CMS
Regeneron Healthcare Solutions, Inc. $10.0004/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927209081 CMS
Mallinckrodt Hospital Products Inc. $99.9904/05/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937502883 CMS
Amgen Inc. $26.5703/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939220709 CMS
Mallinckrodt Hospital Products Inc. $34.9203/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937502881 CMS
Regeneron Healthcare Solutions, Inc. $11.7603/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927209077 CMS
Electromed, Inc. $22.9203/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948228493 CMS
Amgen Inc. $28.0003/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939220707 CMS
AstraZeneca Pharmaceuticals LP $21.6003/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920262847 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.1303/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929850569 CMS
Regeneron Healthcare Solutions, Inc. $29.8203/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927209071 CMS
AstraZeneca Pharmaceuticals LP $21.3403/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920256087 CMS
GlaxoSmithKline, LLC. $25.5902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945137341 CMS
Nabriva Therapeutics, plc $15.1302/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961091393 CMS
Regeneron Healthcare Solutions, Inc. $24.4902/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927209067 CMS
AstraZeneca Pharmaceuticals LP $18.7701/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920242109 CMS
Sandoz Inc. $19.2701/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908855327 CMS
AstraZeneca Pharmaceuticals LP $930.0001/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920222339 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.4101/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887664379 CMS
AstraZeneca Pharmaceuticals LP $13.9701/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920259711 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,033.85 107
PY2020 $2,269.99 91
PY2021 $2,938.48 108
PY2022 $24,391.39 102
PY2023 $35,920.13 115
PY2024 $9,417.58 70
PY2025 $1,914.76 50

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,075.25 12
PY2025 Principal investigator $581,136.01 56
PY2024 Principal investigator $310,956.62 75
PY2023 Principal investigator $98,808.50 45
PY2022 Principal investigator $28,280.22 6
PY2021 Principal investigator $45,322.35 8
PY2020 Recipient $1,100.00 1
PY2020 Principal investigator $8,957.00 1
PY2019 Recipient $8,000.00 4
PY2019 Principal investigator $900.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $17,257.50 12/23/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157434
Principal investigator 1 GlaxoSmithKline, LLC. $36,071.10 11/25/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157444
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/24/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192105120
Principal investigator 1 GlaxoSmithKline, LLC. $5,902.10 11/24/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157453
Principal investigator 1 GlaxoSmithKline, LLC. $4,977.00 11/21/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192105110
Principal investigator 1 GlaxoSmithKline, LLC. $1,592.66 11/19/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192103649
Principal investigator 1 GlaxoSmithKline, LLC. $10,000.00 11/19/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192164298
Principal investigator 1 GlaxoSmithKline, LLC. $1,592.66 11/12/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192164272
Principal investigator 1 GlaxoSmithKline, LLC. $7,203.33 11/05/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192157673
Principal investigator 1 SANOFI US SERVICES INC. $18,363.00 10/20/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123795
Principal investigator 1 GlaxoSmithKline, LLC. $12,729.60 10/17/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192103669
Principal investigator 1 GlaxoSmithKline, LLC. $594.00 10/08/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192164289
Principal investigator 1 GlaxoSmithKline, LLC. $11,904.30 10/02/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192105098
Principal investigator 1 GlaxoSmithKline, LLC. $2,772.97 09/24/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192105134
Principal investigator 1 GlaxoSmithKline, LLC. $5,017.00 09/24/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192157652
Principal investigator 1 SANOFI US SERVICES INC. $15,229.00 09/22/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226123790
Principal investigator 1 GlaxoSmithKline, LLC. $11,000.00 09/17/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192103644
Principal investigator 1 GlaxoSmithKline, LLC. $12,397.45 09/17/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192105127
Principal investigator 1 GlaxoSmithKline, LLC. $2,125.00 09/17/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192157426
Principal investigator 1 SANOFI US SERVICES INC. $8,480.00 09/15/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123786
Principal investigator 1 GlaxoSmithKline, LLC. $9,950.00 09/12/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192164281
Principal investigator 1 GlaxoSmithKline, LLC. $2,233.80 09/08/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157647
Principal investigator 1 GlaxoSmithKline, LLC. $2,414.00 09/03/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192103686
Principal investigator 1 GlaxoSmithKline, LLC. $9,010.80 09/03/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192105115
Principal investigator 1 GlaxoSmithKline, LLC. $1,972.00 08/22/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192164293
Principal investigator 1 SANOFI US SERVICES INC. $6,073.00 08/18/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123782
Principal investigator 1 GlaxoSmithKline, LLC. $18,410.40 08/13/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157430
Principal investigator 1 GlaxoSmithKline, LLC. $900.90 08/01/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103680
Principal investigator 1 GlaxoSmithKline, LLC. $17,300.00 07/25/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192157677
Principal investigator 1 GlaxoSmithKline, LLC. $574.20 07/25/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192164276
Principal investigator 1 GlaxoSmithKline, LLC. $18,024.00 07/18/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192105104
Principal investigator 1 SANOFI US SERVICES INC. $6,741.00 07/14/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123773
Principal investigator 1 GlaxoSmithKline, LLC. $1,709.10 06/16/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157661
Principal investigator 1 SANOFI US SERVICES INC. $6,638.00 06/16/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123769
Principal investigator 1 SANOFI US SERVICES INC. $9,247.00 06/09/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123766
Principal investigator 1 GlaxoSmithKline, LLC. $10,803.60 05/21/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192105140
Recipient GlaxoSmithKline, LLC. $59.77 05/21/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164855
Recipient GlaxoSmithKline, LLC. $163.00 05/21/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164867
Recipient GlaxoSmithKline, LLC. $30.90 05/21/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164872
Recipient GlaxoSmithKline, LLC. $56.92 05/21/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164886
Principal investigator 1 SANOFI US SERVICES INC. $8,879.00 05/12/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123758
Principal investigator 1 GlaxoSmithKline, LLC. $9,336.60 04/23/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192155114
Principal investigator 1 GlaxoSmithKline, LLC. $839.00 04/04/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157457
Principal investigator 1 GlaxoSmithKline, LLC. $799.00 04/04/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192164284
Principal investigator 1 GlaxoSmithKline, LLC. $10,346.40 04/02/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192103675
Principal investigator 1 SANOFI US SERVICES INC. $9,001.00 04/02/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123742
Recipient GlaxoSmithKline, LLC. $20.61 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164302
Recipient GlaxoSmithKline, LLC. $26.77 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164306
Recipient GlaxoSmithKline, LLC. $20.61 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164859
Recipient GlaxoSmithKline, LLC. $49.56 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164864
Recipient GlaxoSmithKline, LLC. $101.38 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164876
Recipient GlaxoSmithKline, LLC. $68.34 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164882
Recipient GlaxoSmithKline, LLC. $388.13 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164891
Recipient GlaxoSmithKline, LLC. $89.26 03/27/2025 Covered Recipient Physician A TWO-PART PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY No dispute reported 06/30/2026 1192164894
Principal investigator 1 GlaxoSmithKline, LLC. $12,500.00 03/14/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192157448
Principal investigator 1 SANOFI US SERVICES INC. $11,100.00 03/10/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123738
Principal investigator 1 GlaxoSmithKline, LLC. $581.00 03/07/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103637
Principal investigator 1 GlaxoSmithKline, LLC. $755.00 03/07/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157665
Principal investigator 1 GlaxoSmithKline, LLC. $1,698.00 03/07/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192157669
Principal investigator 1 GlaxoSmithKline, LLC. $7,101.90 02/25/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157439
Principal investigator 1 SANOFI US SERVICES INC. $12,500.00 02/18/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226123734
Principal investigator 1 SANOFI US SERVICES INC. $11,760.00 02/04/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123732
Principal investigator 1 GlaxoSmithKline, LLC. $4,271.40 02/03/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157657
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,295.60 01/31/2025 Non-covered Recipient Entity
FRANK HULL
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185554873
Principal investigator 1 AstraZeneca Pharmaceuticals LP $92,122.80 01/29/2025 Non-covered Recipient Entity
FRANK HULL
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185554871
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,961.74 01/17/2025 Non-covered Recipient Entity
FRANK HULL
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1185554875
Principal investigator 1 GlaxoSmithKline, LLC. $1,475.10 01/13/2025 Non-covered Recipient Entity
HULL AND HULL MEDICAL SPECIALISTS LLP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192103661
Principal investigator 1 SANOFI US SERVICES INC. $15,102.00 01/13/2025 Non-covered Recipient Entity
Hull Hull Medical Specialists Llp Broward Pulmonary And Sleep Specialists
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226123750